EIP-1 and EIP-3 genes, envelope-interacting proteins, EIP-1 and EIP-3

US6469153B1 · kind B1 · utility

Assignee

• The Trustees of Columbia University in the City of New York · US

Inventors

• Stephen P. Goff · Orefield, US
• Xingqiang Li · Yinchuan, CN

Key dates

• Filing date: May 20, 1998
• Grant date: Oct 22, 2002
• Expiry date: May 20, 2018

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2740/16045
• WIPO field: Biotechnology
• WIPO sector: Chemistry

Abstract

This invention provides isolated nucleic acid molecules encoding envelope-interacting protein-1 and envelope-interacting protein-3. This invention provides fusion proteins comprising EIP-1, EIP-3, or fragments thereof and a second peptide. This invention provides vectors comprising the isolated nucleic acid molecule, encoding mammalian EIP-1 and EIP-3. This invention provides plasmid designated pCGN-EIP-l and pCGN-EIP-3. This invention provides purified mammalian EIP-1 and EIP-3 proteins. This invention provides monoclonal or polyclonal antibodies directed to epitopes of an EIP-1 or an EIP-3. This invention provides a method of increasing transduction efficieny of a retrovirus on target cells comprising: a) incubating an envelope-interacting protein with a retrovirus; and b) transducing the target cells with the retrovirus. This invention provide methods of treating patient with a therapeutic gene comprising use of transducing viruses incubated with an effective amount of an envelope-interacting protein effective to enhance retroviral infectivity. This invention also provides pharmaceutical composition comprising an envelope-interacting protein bound retroviral virion comprising a …